tiprankstipranks
Hutchmed licenses fruquintinib to Takeda Pharmaceutical for up to $1.13B
The Fly

Hutchmed licenses fruquintinib to Takeda Pharmaceutical for up to $1.13B

Hutchmed (HCM) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical (TAK) to further the global development, commercialization and manufacturing of fruquintinib outside of mainland China, Hong Kong and Macau, where it is marketed by Hutchmed. Hutchmed Limited will receive up to $1.13B including $400 million upfront on closing as well as potential regulatory, development and commercial sales milestone payments, plus royalties on net sales. Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3. Fruquintinib is orally administered and has the potential to be used across subtypes of metastatic colorectal cancer, regardless of biomarker status.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on HCM:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles